Australia Markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.90+0.66 (+4.63%)
At close: 04:00PM EDT
14.90 0.00 (0.00%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.41
Open13.65
Bid13.55 x 1300
Ask14.87 x 1000
Day's range13.95 - 14.93
52-week range12.52 - 38.80
Volume340,400
Avg. volume511,103
Market cap688.592M
Beta (5Y monthly)1.04
PE ratio (TTM)2.15
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

    If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, May 24, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) submitted by CSL Behring for etranacogene dezapar

  • GlobeNewswire

    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass. and AMSTERDAM, May 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment. The equity grants were approved on April 29, 2022 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the employees received

  • GlobeNewswire

    uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C. "Our presentations at ASGCT showcase the exceptional work of our uniQu